sodium 4-hydroxypentanoateDISCONTINUED SEE H992000 - CAS 56279-37-9
Catalog: |
BB057746 |
Product Name: |
sodium 4-hydroxypentanoateDISCONTINUED SEE H992000 |
CAS: |
56279-37-9 |
Synonyms: |
sodium 4-hydroxypentanoate; sodium; 4-hydroxypentanoate; GHV sodium salt; sodium 4-hydroxyvalerate; sodium4-hydroxypentanoate; Pentanoic acid, 4-hydroxy-, monosodium salt |
IUPAC Name: | sodium4-hydroxypentanoate |
Description: | sodium 4-hydroxypentanoate (cas# 56279-37-9) is a useful research chemical. |
Molecular Weight: | 140.11 |
Molecular Formula: | C5H9O3-·Na+ |
Canonical SMILES: | CC(CCC(=O)[O-])O.[Na+] |
InChI: | InChI=1S/C5H10O3.Na/c1-4(6)2-3-5(7)8/h4,6H,2-3H2,1H3,(H,7,8)/q+1/p-1 |
InChI Key: | MEGFTCUCXBRUTB-UHFFFAOYSA-M |
Melting Point: | 145-148°C |
Solubility: | Water (Slightly) |
Appearance: | White to Off-White Solid |
Storage: | 4°C |
References: | Maitre, M., et al. PCT Int. Appl. WOВ 2013024028В A1В 20130221. Feb 21, 2013. |
GHS Hazard Statement: | H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] |
Precautionary Statement: | P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
GB-2595261-A | Enzyme-catalytic method for the direct stereoselective synthesis of gamma-(acetyloxy) carboxylic acids | 20200519 |
AU-2015274530-A1 | Beta-lactamase inhibitors | 20140611 |
AU-2015274530-B2 | Beta-lactamase inhibitors | 20140611 |
CA-2950917-A1 | Beta-lactamase inhibitors | 20140611 |
EP-3154989-A1 | Beta-lactamase inhibitors | 20140611 |
KR-20170018353-A | Beta-lactamase inhibitors | 20140611 |
RU-2686740-C2 | Beta-lactamase inhibitors | 20140611 |
US-2016264598-A1 | Beta-lactamase inhibitors | 20140611 |
US-2017226135-A1 | Beta-lactamase inhibitors | 20140611 |
US-2017342092-A1 | Beta-lactamase inhibitors | 20140611 |
GB-2595261-A | Enzyme-catalytic method for the direct stereoselective synthesis of gamma-(acetyloxy) carboxylic acids | 20200519 |
AU-2015274530-A1 | Beta-lactamase inhibitors | 20140611 |
AU-2015274530-B2 | Beta-lactamase inhibitors | 20140611 |
CA-2950917-A1 | Beta-lactamase inhibitors | 20140611 |
EP-3154989-A1 | Beta-lactamase inhibitors | 20140611 |
KR-20170018353-A | Beta-lactamase inhibitors | 20140611 |
RU-2686740-C2 | Beta-lactamase inhibitors | 20140611 |
US-2016264598-A1 | Beta-lactamase inhibitors | 20140611 |
US-2017226135-A1 | Beta-lactamase inhibitors | 20140611 |
US-2017342092-A1 | Beta-lactamase inhibitors | 20140611 |
Complexity: | 84.3 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 2 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 140.04493843 |
Formal Charge: | 0 |
Heavy Atom Count: | 9 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 140.04493843 |
Rotatable Bond Count: | 3 |
Topological Polar Surface Area: | 60.4Ų |
Undefined Atom Stereocenter Count: | 1 |
Undefined Bond Stereocenter Count: | 0 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS